Posts

Real-World Experience with 177Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval | Journal of Nuclear Medicine

Image
Real-World Experience with 177Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval | Journal of Nuclear Medicine jnm.snmjournals.org Abuzar Moradi Tuchayi, Surekha Yadav , Fei Jiang , Sarasa T. Kim , Rachelle K. Saelee , Amanda Morley , Roxanna Juarez , Courtney Lawhn-Heath , Yingbing Wang , Ivan de Kouchkovsky and Thomas A. Hope Journal of Nuclear Medicine May 2024, 65 (5) 735-739; DOI: https://doi.org/10.2967/jnumed.123.266842 Abstract We report our initial real-world experience with 177 Lu-PSMA-617 radioligand therapy.   Methods: We performed a retrospective review of patients treated with 177 Lu-PSMA-617. Pretreatment PSMA PET, laboratory findings, overall survival, a fall in prostate-specific antigen by 50% (PSA50), and toxicities were evaluated.  Results: Ninety-nine patients were included. Sixty patients achieved a PSA50. Seven of 18 (39%) patients who d
Post a Comment
Read more

Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm? | Journal of Nuclear Medicine

Image
Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm? | Journal of Nuclear Medicine jnm.snmjournals.org Paul Viscuse, Michael Devitt and Robert Dreicer   Summary Use of  177 Lu for Targeted Radionuclide Therapy for mCRPC has garnered great interest recently, in some cases even yielding remission. Here is a summary of the key points from the review article on the clinical management of advanced prostate cancer and the role of radiopharmaceutical therapy: Metastatic hormone-sensitive prostate cancer is optimally treated with androgen deprivation therapy (ADT) intensified with docetaxel chemotherapy and/or androgen receptor signaling inhibitors (ARSIs) like abiraterone, enzalutamide, apalutamide, or darolutamide. This has significantly improved overall survival. After progression to metastatic castration-resistant prostate cancer (mCRPC), trea
Post a Comment
Read more

keto diet plus immunotherapy may reduce prostate cancer

Image
recent breakthroughs in cancer immunotherapy The webinar discusses recent breakthroughs in cancer immunotherapy, which involves harnessing the body's own immune system to fight cancer. The immune system is usually very good at attacking foreign invaders like viruses, but has a harder time recognizing and attacking cancer cells. Dr. Allison and his colleagues discovered that there are "brakes" on immune cells called checkpoints that normally prevent them from attacking the body's own healthy cells. Tumor cells often take advantage of these checkpoints to evade attack by immune cells. Dr. Allison developed antibody drugs that release these brakes, allowing immune cells to vigorously attack tumors. In clinical trials, these checkpoint inhibitor drugs have produced very long-lasting responses in some patients with advanced cancers like melanoma.   Dr. Freeman discovered another important checkpoint called PD-1. Drugs targeting PD-1 have also shown great prom
Post a Comment
Read more

Prostate Cancer Breakthrough: Urine Test Avoids Unnecessary Biopsies

Image
Prostate Cancer Breakthrough: Urine Test Avoids Unnecessary Biopsies scitechdaily.com Vanderbilt University Medical Center MyProstateScore 2.0, a urine test for prostate cancer, offers high accuracy and fewer needless biopsies compared to traditional PSA tests, according to recent research. A study in JAMA Oncology reveals that MyProstateScore 2.0, a new urine test analyzing 18 genes, surpasses PSA in detecting significant prostate cancers and could reduce unnecessary biopsies by up to 42%. A new urine test that measures 18 genes associated with prostate cancer provides higher accuracy for detecting clinically significant cancers than PSA and other existing biomarker tests, according to a study published on April 18 in JAMA Oncology . The urine test, MyProstateScore 2.0 (MPS2), was shown to meaningfully reduce unnecessary prostate biopsies while providin
Post a Comment
Read more